Description du projet
Un traqueur portable pour la surveillance des informations biochimiques des patients
Le secteur de la médecine personnalisée se trouve confronté à des difficultés importantes en raison de la pénurie des infrastructures médicales causée par la pandémie de COVID-19. L’un des obstacles majeurs a été l’absence de surveillance en temps réel des indicateurs de santé des patients. Cette modalité et les nombreux avantages qui en découlent sont ainsi impossibles à mettre en œuvre. Le projet CytoTrack, financé par l’UE, compte résoudre ce problème en proposant un système portable capable de suivre de manière continue et non invasive les informations biochimiques, et de fournir des indicateurs de santé cruciaux en temps réel. CytoTrack prévoit également d’assurer la surveillance des patients à risque pour détecter des signes susceptibles de suggérer une infection à des virus de type grippal, ou à d’autres maladies. Cela pourrait prémunir les patients contre un risque de défaillance organique potentiellement mortel.
Objectif
Xsensio is an innovation-driven Swiss company dedicated to solving one of the biggest challenges for
personalized medicine: the lack of real-time, continuous monitoring of health parameters in patients. Xsensio has built the highly modular CytoTrack breakthrough sensing platform to continuously and non-invasively track biochemical information as a wearable system and offer critical health insight in real time. CytoTrack has potential to continuously monitor inflammatory markers that tend to suddenly increase in at-risk patients, when infected by influenza-related viruses (e.g. COVID-19), or when undergoing powerful oncology treatments, exposing them to severe life-threatening organ failure. We have a passionate team of 7 PhDs, engineers and business people with expertise ranging from biochemistry and nanofluidics to data analytics and healthcare marketing, all committed to making the Lab-on-SkinTM a daily reality impacting tomorrow' s healthcare. In 2018, a 2-year agreement was signed with a top 10 biopharma company to leverage our cutting-edge solution for their oncology pipeline. Xsensio received many awards internationally, e.g. CES Innovation Award 2020 given to the world’s best innovations. Xsensio plans to grow a large, successful company, that becomes a European success story. While the preferred exit is an IPO, Xsensio remains open to other opportunities, including a trade sale. The milestones targeted in this proposal are critical to the future of Xsensio: they allow the company to build a strong platform of game-changing complementary diagnostic monitoring for the pharma industry to help predict the likely response and likely severe toxicity of their drugs during drug development and post-market surveillance. Investment from the EIC is critical to Xsensio as efforts to raise funds have proven to be challenging in the absence of preclinical data, putting the validation phase at risk of being delayed. Xsensio welcomes blended finance from the EC.
Champ scientifique
Mots‑clés
Programme(s)
Régime de financement
SME-2 - SME instrument phase 2Coordinateur
1015 Lausanne
Suisse
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.